Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BLU-5937 ER · BLU-5937

Small molecule · developed by Bellus Health Inc. - a GSK company

Phase 1 Most advanced trial (none active)
GSK Developer
1 Registered trials

What is BLU-5937 ER?

BLU-5937 ER is an extended-release oral formulation studied in a clinical trial in healthy subjects, with cough as a listed trial condition.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BLU-5937
Drug type
Small molecule
Therapy area
Respiratory
Developer
Bellus Health Inc. - a GSK company (GSK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
TB7D2H7MZZ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05570539 Phase 1 Cough Completed GSK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

CoughHealthy

More from Bellus Health Inc. - a GSK company

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the GSK page.

Follow GSK, the company behind BLU-5937 ER

See GSK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GSK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.